Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

MET-233I

Stage Phase 1/2

Sponsor Pfizer

Route injection

Sources

registry, as of 2026-11-02

https://clinicaltrials.gov/study/NCT06924320

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Pfizer. Enrollment 201. Conditions Obesity and Obesity-related Medical Conditions. This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.

ClinicalTrials.gov NCT06924320 protocol and results modules

registry, as of 2026-05-26Stale

https://clinicaltrials.gov/study/NCT07022977

A Study of MET233 in Individuals With Obesity or Overweight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 144. Conditions Obesity and Overweight. The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. This study will be conducted in four parts: * Part A will evalu

ClinicalTrials.gov NCT07022977 protocol and results modules

Studies

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

Registry NCT06924320

Phase Phase 1/2

Status Completed

Enrollment 201

Start 2025-03-06

Primary completion 2026-09-29

Study completion 2026-09-29

Catalyst Primary completion. 2026-09-29. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Part A Cohort

Regimen every 4 weeks

Weeks 4

Population Obesity and Obesity-related Medical Conditions

Part B Cohort

Regimen every 4 weeks

Weeks 4

Population Obesity and Obesity-related Medical Conditions

Part C Cohort

Regimen every 4 weeks

Weeks 4

Population Obesity and Obesity-related Medical Conditions

Part D Cohort

Regimen every 4 weeks

Weeks 4

Population Obesity and Obesity-related Medical Conditions

Part E Cohort

Regimen every 4 weeks

Weeks 4

Population Obesity and Obesity-related Medical Conditions

Part G Cohort

Regimen every 4 weeks

Weeks 4

Population Obesity and Obesity-related Medical Conditions

A Study of MET233 in Individuals With Obesity or Overweight

Registry NCT07022977

Phase Phase 1

Status Completed

Enrollment 144

Start 2024-11-06

Primary completion 2026-04-21

Study completion 2026-04-21

Catalyst Primary completion. 2026-04-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

(Part A) MET233

Regimen once weekly

Weeks 12

Comparator placebo

Population Obesity and Overweight

(Part A) Placebo

Regimen once weekly

Weeks 12

Population Obesity and Overweight

(Part B) MET233

Regimen weekly

Weeks 12

Comparator placebo

Population Obesity and Overweight

(Part B) Placebo

Regimen weekly

Weeks 12

Population Obesity and Overweight

(Part C) MET233

Regimen once monthly

Weeks 12

Comparator placebo

Population Obesity and Overweight

(Part C) Placebo

Regimen once monthly

Weeks 12

Population Obesity and Overweight

(Part D) MET233

Regimen once monthly

Weeks 12

Comparator placebo

Population Obesity and Overweight

(Part D) Placebo

Regimen once monthly

Weeks 12

Population Obesity and Overweight